Skip to content

Adenovirus Vaccine Vectors and HIV Acquisition Risk: The View from the Summit

Publication • 2013
On September 19th, 2013, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a daylong mini-summit to discuss the safety of adenovirus vaccine vectors in populations at risk for HIV infection.

A Necessary Transformation

TAGline • 2013
Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research By Lindsay McKenna An example of a multi-arm multi-stage (MAMS) phase II trial design. At the first interim analysis, novel regimen 2 is considered to lack sufficient benefit compared with the control and is not taken forward to stage 2. At…

Beyond ARVs: Advocacy for Non-AIDS Disease Management

TAGline • 2013
by Tim Horn Fact: If we’re going to make headway in preventing and treating non-AIDS-related health complications among people with HIV, which are very much on the rise and a serious risk to disease-free survival, we’re going to need the full-on cooperation of pharmaceutical companies manufacturing and developing drugs for non-HIV diseases. Enter Micardis (telmisartan),…

Treatment Action Group and European AIDS Treatment Group Applaud UNITAID Agreement to Reduce the Cost of GeneXpert Rapid TB Test

Statement / Press • 2012
Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG) welcome the announcement that a deal has been reached among PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB).

Retrofitting for Purpose: Treatment Optimization

Pipeline • 2012
JULY 2012 By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In June 2010, the WHO and UNAIDS launched Treatment 2.0, a strategic approach to the achievement of universal access to antiretroviral therapy (ART) and to making the most of the role of…

The Future of TB in the United States: Going, or Growing?

TAGline • 2012
By Erica Lessem This summer, Treatment Action Group (TAG) and its partners in fighting tuberculosis (TB) issued a call for zero TB deaths, zero new TB infections, and zero suffering from TB. Yet the U.S., long a leader in TB elimination efforts, is in jeopardy of losing ground in the struggle to get to zero.…

Hepatitis C Drug Development Goes from Pony Ride to Rocket Launch

Pipeline • 2012
December 2012 Update – Cure rates presented at the American Association for the Study of Liver Diseases (AASLD) July 2012 By Tracy Swan and Karyn Kaplan Dedicated to Michael Carden A fabulous, kind, brilliant, and hilarious friend and colleague 1971–2012 Special thanks to Jules Levin Introduction Hepatitis C virus (HCV) infection is curable, although it…

Does Obama’s 2013 Budget Herald the End of PEPFAR?

TAGline • 2012
Devastating Funding Proposal Undermines the Global Fight Against AIDS by Coco Jervis A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Cuts of this magnitude could lead to…

The Tuberculosis Treatment Pipeline

Pipeline • 2012
Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will. As a result of poor treatment options and inadequate administration of care, increasingly intractable drug-resistant…

Hepatitis C Treatment Access: Spotlight on Thailand/Asia

Pipeline • 2012
July 2012 By Karyn Kaplan According to the Universal Declaration of Human Rights and subsequent treaties, all people have a fundamental right to the highest attainable standard of health, as well as a right to the benefits of scientific progress and its applications. Yet many governments in the global South are unable to even progressively…
Back To Top